132 related articles for article (PubMed ID: 30720117)
1. Expression of protein disulfide isomerase A3 and its clinicopathological association in gastric cancer.
Shimoda T; Wada R; Kure S; Ishino K; Kudo M; Ohashi R; Fujita I; Uchida E; Yoshida H; Naito Z
Oncol Rep; 2019 Apr; 41(4):2265-2272. PubMed ID: 30720117
[TBL] [Abstract][Full Text] [Related]
2. Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up.
Kure S; Chiba T; Ebina A; Toda K; Jikuzono T; Motoda N; Mitani H; Sugitani I; Takeuchi K; Ohashi R
Endocr J; 2022 Mar; 69(3):273-281. PubMed ID: 34732604
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of PDIA3 inhibits gastric cancer cell growth through cell cycle regulation.
Yang M; Li Q; Yang H; Li Y; Lu L; Wu X; Liu Y; Li W; Shen J; Xiao Z; Zhao Y; Du F; Chen Y; Deng S; Cho CH; Li X; Li M
Biomed Pharmacother; 2024 Apr; 173():116336. PubMed ID: 38412717
[TBL] [Abstract][Full Text] [Related]
4. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
Front Immunol; 2022; 13():837512. PubMed ID: 35401558
[TBL] [Abstract][Full Text] [Related]
5. Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer.
Song D; Guo M; Wu K; Hao J; Nie Y; Fan D
Acta Biochim Biophys Sin (Shanghai); 2021 Aug; 53(9):1216-1226. PubMed ID: 34363072
[TBL] [Abstract][Full Text] [Related]
6. Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies.
Caorsi C; Niccolai E; Capello M; Vallone R; Chattaragada MS; Alushi B; Castiglione A; Ciccone G; Mautino A; Cassoni P; De Monte L; Álvarez-Fernández SM; Amedei A; Alessio M; Novelli F
Transl Res; 2016 May; 171():17-28.e1-2. PubMed ID: 26772958
[TBL] [Abstract][Full Text] [Related]
7. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.
Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH
Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y
World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of protein disulfide-isomerase A3 isoforms, PDIA3 and PDIA3N, in human prostate cancer cell lines representing different stages of prostate cancer.
Diaz Cruz MA; Karlsson S; Szekeres F; Faresjö M; Lund D; Larsson D
Mol Biol Rep; 2021 Mar; 48(3):2429-2436. PubMed ID: 33761087
[TBL] [Abstract][Full Text] [Related]
10. Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression.
Zhu Y; Cai L; Guo J; Chen N; Yi X; Zhao Y; Cai J; Wang Z
Tumour Biol; 2016 Oct; 37(10):14009-14023. PubMed ID: 27492604
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma.
Takata H; Kudo M; Yamamoto T; Ueda J; Ishino K; Peng WX; Wada R; Taniai N; Yoshida H; Uchida E; Naito Z
Oncol Lett; 2016 Dec; 12(6):4896-4904. PubMed ID: 28101228
[TBL] [Abstract][Full Text] [Related]
12. Oxidatively Modified Protein-Disulfide Isomerase-Associated 3 Promotes Dyskerin Pseudouridine Synthase 1-Mediated Malignancy and Survival of Hepatocellular Carcinoma Cells.
Ko E; Kim JS; Ju S; Seo HW; Chang Y; Kang JA; Park SG; Jung G
Hepatology; 2018 Nov; 68(5):1851-1864. PubMed ID: 29672884
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of protein disulfide isomerase A3 in Egyptian bladder cancer patients.
Safwat El-Deeb O; Abd-Ellatif RN; Othman TS; Afifi M; El-Magd M
Gene; 2019 Apr; 693():76-83. PubMed ID: 30708028
[TBL] [Abstract][Full Text] [Related]
14. PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer.
Ramos FS; Serino LT; Carvalho CM; Lima RS; Urban CA; Cavalli IJ; Ribeiro EM
Genet Mol Res; 2015 Jun; 14(2):6960-7. PubMed ID: 26125904
[TBL] [Abstract][Full Text] [Related]
15. PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation.
Chiavari M; Ciotti GMP; Canonico F; Altieri F; Lacal PM; Graziani G; Navarra P; Lisi L
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153019
[TBL] [Abstract][Full Text] [Related]
16. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
17. Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer.
Nam KH; Lee BL; Park JH; Kim J; Han N; Lee HE; Kim MA; Lee HS; Kim WH
Pathobiology; 2013; 80(2):87-94. PubMed ID: 23038627
[TBL] [Abstract][Full Text] [Related]
18. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression.
Kanda M; Nomoto S; Oya H; Takami H; Shimizu D; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S214-21. PubMed ID: 25743330
[TBL] [Abstract][Full Text] [Related]
19. A decision tree-based combination of ezrin-interacting proteins to estimate the prognostic risk of patients with esophageal squamous cell carcinoma.
He JZ; Wu ZY; Wang SH; Ji X; Yang CX; Xu XE; Liao LD; Wu JY; Li EM; Zhang K; Xu LY
Hum Pathol; 2017 Aug; 66():115-125. PubMed ID: 28603065
[TBL] [Abstract][Full Text] [Related]
20. The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
Popiela T; Kulig J; Kołodziejczyk P;
Przegl Lek; 2000; 57 Suppl 5():9-13. PubMed ID: 11202309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
